scholarly journals Lactococcus lactis Strain Plasma Intake Suppresses the Incidence of Dengue Fever-like Symptoms in Healthy Malaysians: A Randomized, Double-Blind, Placebo-Controlled Trial

Nutrients ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 4507
Author(s):  
Chee-Sieng Khor ◽  
Ryohei Tsuji ◽  
Hai-Yen Lee ◽  
Siti-Sarah Nor’e ◽  
Norhidayu Sahimin ◽  
...  
Keyword(s):  
Dengue Fever ◽  
Lactococcus Lactis ◽  
Clinical Symptoms ◽  
Controlled Trial ◽  
Serum Antibody ◽  
Oral Intake ◽  
Double Blind ◽  
Lactis Strain ◽  
Antigen Tests ◽  
Study Sites

Dengue fever (DF) is a mosquito-borne disease still with no effective treatment or vaccine available. A randomized, placebo-controlled, double-blinded, parallel-group trial was undertaken to evaluate the efficacy of oral intake of Lactococcus lactis strain plasma (LC-Plasma) on the presentation and severity of DF-like symptoms among healthy volunteers. Study participants (320) were assigned into two groups, and consumed either placebo or LC-Plasma tablets (approximately 100 billion cells/day) for 8 weeks. The clinical symptoms of DF were self-recorded through questionnaires, and exposure to DENV was determined by serum antibody and/or DENV antigen tests. No significant differences between groups were observed for exposure to DENV, or the symptomatic ratio. Results obtained showed that participants from the LC-Plasma group reported a significant reduction in the cumulative incidence days of DF-like symptoms, which include fever (p < 0.001), muscle pain (p < 0.005), joint pain (p < 0.001), and pain behind the eyes (p < 0.001), compared to that of the placebo group. Subgroup analysis revealed a significantly (p < 0.05) reduced severity score in the LC-Plasma group when study sites were separately analyzed. Overall, our findings suggest that LC-Plasma supplementation reduces the cumulative days with DF-like symptoms, and the severity of the symptoms. Daily oral intake of LC-Plasma, hence, is shown to mitigate the DF-like symptoms.

scholarly journals The Effects of Dietary Supplementation of Lactococcus lactis Strain Plasma on Skin Microbiome and Skin Conditions in Healthy Subjects—A Randomized, Double-Blind, Placebo-Controlled Trial

2021 ◽  
Vol 9 (3) ◽  
pp. 563
Author(s):  
Ryohei Tsuji ◽  
Kamiyu Yazawa ◽  
Takeshi Kokubo ◽  
Yuumi Nakamura ◽  
Osamu Kanauchi
Keyword(s):  
Gene Expression ◽  
Lactococcus Lactis ◽  
Healthy Subjects ◽  
Controlled Trial ◽  
Dietary Supplementation ◽  
Skin Microbiome ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Lactis Strain ◽  
Skin Conditions

(1) Background: Lactococcus lactis strain Plasma (LC-Plasma) is a unique strain which directly activates plasmacytoid dendritic cells, resulting in the prevention against broad spectrum of viral infection. Additionally, we found that LC-Plasma intake stimulated skin immunity and prevents Staphylococcus aureus epicutaneous infection. The aim of this study was to investigate the effect of LC-Plasma dietary supplementation on skin microbiome, gene expression in the skin, and skin conditions in healthy subjects. (2) Method: A randomized, double-blind, placebo-controlled, parallel-group trial was conducted. Seventy healthy volunteers were enrolled and assigned into two groups receiving either placebo or LC-Plasma capsules (approximately 1 × 1011 cells/day) for 8 weeks. The skin microbiome was analyzed by NGS and qPCR. Gene expression was analyzed by qPCR and skin conditions were diagnosed by dermatologists before and after intervention. (3) Result: LC-Plasma supplementation prevented the decrease of Staphylococcus epidermidis and Staphylococcus pasteuri and overgrowth of Propionibacterium acnes. In addition, LC-Plasma supplementation suggested to increase the expression of antimicrobial peptide genes but not tight junction genes. Furthermore, the clinical scores of skin conditions were ameliorated by LC-Plasma supplementation. (4) Conclusions: Our findings provided the insights that the dietary supplementation of LC-Plasma might have stabilizing effects on seasonal change of skin microbiome and skin conditions in healthy subjects.

scholarly journals Oral intake of heat-killed cells of Lactococcus lactis strain H61 promotes skin health in women

2012 ◽  
Vol 1 ◽  
Author(s):  
Hiromi Kimoto-Nira ◽  
Reiji Aoki ◽  
Keisuke Sasaki ◽  
Chise Suzuki ◽  
Koko Mizumachi
Keyword(s):  
Placebo Group ◽  
Environmental Change ◽  
Lactococcus Lactis ◽  
Controlled Trial ◽  
Oral Intake ◽  
Hair Follicles ◽  
Skin Hydration ◽  
Ageing Population ◽  
Skin Elasticity ◽  
Double Blind

AbstractWe conducted a double-blind, placebo-controlled trial to evaluate the effect of heat-killed cells of Lactococcus lactis strain H61 on various skin properties of Japanese women. Volunteers (age 31–62 years) were randomly assigned to receive test food with or without 60 mg of heat-killed strain H61 (fifteen women in each group; H61 and control groups, respectively) daily for 8 weeks. Results were analysed for three age categories (30s, 40s and 50–60s). Compared with that at week 0, skin hydration at the inner forearm at weeks 4 and 8 decreased in all volunteers (except those in their 50–60s) because of the environmental change from autumn to winter. The oldest H61 group maintained skin hydration at the inner forearm throughout the study. Skin elasticity and melanin content in the cheek decreased and sebum content increased throughout the test period due to seasonal environmental change, regardless of age or H61 treatment. Self-evaluation scores for apparent hair follicles and dryness of the throat at week 8 were higher in the overall H61 group than in the combined placebo group. The 30s H61 group noted marked improvements in self-surveyed skin elasticity at week 8 compared with at week 0 and with the placebo group at week 8. The results of the present study indicate that oral intake of heat-killed cells of L. lactis strain H61 can improve some skin properties and body characteristics in women. This strain would probably be useful in increasing the quality of life in an ageing population.

scholarly journals Effect of oral intake of a Lactococcus lactis strain on skin properties of women ^|^mdash;a Pilot Study^|^mdash;

2012 ◽  
Vol 83 (3) ◽  
pp. 307-313 ◽  
Author(s):  
Hiromi KIMOTO-NIRA ◽  
Reiji AOKI ◽  
Keisuke SASAKI ◽  
Chise SUZUKI ◽  
Koko MIZUMACHI
Keyword(s):  
Pilot Study ◽  
Lactococcus Lactis ◽  
Oral Intake ◽  
Lactis Strain

scholarly journals PROVIT: Supplementary Probiotic Treatment and Vitamin B7 in Depression—A Randomized Controlled Trial

Nutrients ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3422
Author(s):  
Eva Z. Reininghaus ◽  
Martina Platzer ◽  
Alexandra Kohlhammer-Dohr ◽  
Carlo Hamm ◽  
Sabrina Mörkl ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Clinical Symptoms ◽  
Psychiatric Symptoms ◽  
Controlled Trial ◽  
Intervention Group ◽  
Double Blind ◽  
16S Rrna Analysis ◽  
Brain Functions ◽  
Β Diversity ◽  
Probiotic Treatment

Gut microbiota are suspected to affect brain functions and behavior as well as lowering inflammation status. Therefore, an effect on depression has already been suggested by recent research. The aim of this randomized double-blind controlled trial was to evaluate the effect of probiotic treatment in depressed individuals. Within inpatient care, 82 currently depressed individuals were randomly assigned to either receive a multistrain probiotic plus biotin treatment or biotin plus placebo for 28 days. Clinical symptoms as well as gut microbiome were analyzed at the begin of the study, after one and after four weeks. After 16S rRNA analysis, microbiome samples were bioinformatically explored using QIIME, SPSS, R and Piphillin. Both groups improved significantly regarding psychiatric symptoms. Ruminococcus gauvreauii and Coprococcus 3 were more abundant and β-diversity was higher in the probiotics group after 28 days. KEGG-analysis showed elevated inflammation-regulatory and metabolic pathways in the intervention group. The elevated abundance of potentially beneficial bacteria after probiotic treatment allows speculations on the functionality of probiotic treatment in depressed individuals. Furthermore, the finding of upregulated vitamin B6 and B7 synthesis underlines the connection between the quality of diet, gut microbiota and mental health through the regulation of metabolic functions, anti-inflammatory and anti-apoptotic properties. Concluding, four-week probiotic plus biotin supplementation, in inpatient individuals with a major depressive disorder diagnosis, showed an overall beneficial effect of clinical treatment. However, probiotic intervention compared to placebo only differed in microbial diversity profile, not in clinical outcome measures.

scholarly journals Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study)

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Yifei Zhang ◽  
Yanyun Gu ◽  
Huahui Ren ◽  
Shujie Wang ◽  
Huanzi Zhong ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Gut Microbiome ◽  
Controlled Trial ◽  
Oral Intake ◽  
Glycated Haemoglobin ◽  
Double Blind ◽  
Promising Target ◽  
Bacteriostatic Agent ◽  
Gastrointestinal Side Effects

Abstract Human gut microbiome is a promising target for managing type 2 diabetes (T2D). Measures altering gut microbiota like oral intake of probiotics or berberine (BBR), a bacteriostatic agent, merit metabolic homoeostasis. We hence conducted a randomized, double-blind, placebo-controlled trial with newly diagnosed T2D patients from 20 centres in China. Four-hundred-nine eligible participants were enroled, randomly assigned (1:1:1:1) and completed a 12-week treatment of either BBR-alone, probiotics+BBR, probiotics-alone, or placebo, after a one-week run-in of gentamycin pretreatment. The changes in glycated haemoglobin, as the primary outcome, in the probiotics+BBR (least-squares mean [95% CI], −1.04[−1.19, −0.89]%) and BBR-alone group (−0.99[−1.16, −0.83]%) were significantly greater than that in the placebo and probiotics-alone groups (−0.59[−0.75, −0.44]%, −0.53[−0.68, −0.37]%, P < 0.001). BBR treatment induced more gastrointestinal side effects. Further metagenomics and metabolomic studies found that the hypoglycaemic effect of BBR is mediated by the inhibition of DCA biotransformation by Ruminococcus bromii. Therefore, our study reports a human microbial related mechanism underlying the antidiabetic effect of BBR on T2D. (Clinicaltrial.gov Identifier: NCT02861261).

RESTING MYOCARDIAL ISCHEMIA AFTER INTRAVENOUS INFUSION OF BM 13.177, A THROMBOXANE RECEPTOR ANTAGONIST

1987 ◽  
Author(s):  
W Terres ◽  
W Kupper ◽  
C Hamm ◽  
W Bleifeld
Keyword(s):  
Myocardial Ischemia ◽  
Receptor Antagonist ◽  
Clinical Symptoms ◽  
Ex Vivo ◽  
Controlled Trial ◽  
Double Blind ◽  
Thromboxane Receptor ◽  
Exertional Angina ◽  
Thromboxane Receptors ◽  
Thromboxane Receptor Antagonist

We conducted a double blind placebo controlled trial of BM 13.177, a thromboxane receptor antagonist, given intravenously in patients (PTS) with stenoses >70 % of the left anterior descending coronary artery and stable exertional angina pectoris (AP). The study had to be stopped after enrollment of 8 PTS, because 2 had developed resting AP after initiation of the study medication. Both proved to belong to the 4 PTS who had received BM 13.177 (12.5 mg/min). While in one PT, AP was mild, transient and associated with only slight decreases in coronary sinus blood flow (CSBF) and myocardial lactate extraction (MLE), in the other, AP was severe and persisted for 30 minutes in spite of antianginal therapy. Severe clinical symptoms in this PT were associated with a marked fall in MLE from +24 to -121 %. Two PTS under BM 13.177 and 4 on placebo underwent supraventricular stimulation. For both groups, no change in clinical symptoms, CSBF or MLE occured in comparison to a former control stimulation without medication. BM 13.177 led to an inhibition of ex vivo platelet aggregation induced by collagen 1 pg/ml (mean reduction in rate of aggregation by 41 %, p< 0.05), while aggregation was not influenced with collagen 5 μg/ml or ADP. This effect of BM on platelets is explained by its thromboxane receptor blocking properties. The induction of resting myocardial ischemia, however, in 2 of 4 PTS with formerly stable exertional AP may have been the result of either a coronary steal mechanism or an intrinsic stimulation of vascular thromboxane receptors, followed by coronary vasoconstriction.

A Review of Homoeopathic Research in the Prevention and Treatment of Dengue Fever

2019 ◽  
Vol 32 (01) ◽  
pp. 010-017
Author(s):  
Ramesh Supadu Bawaskar ◽  
Vaishali Haribhau Shinde
Keyword(s):  
Clinical Study ◽  
Dengue Fever ◽  
Controlled Trial ◽  
Major Public Health Problem ◽  
Community Based ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Prevention And Treatment ◽  
Comparative Clinical Study

Introduction Dengue ranks as the most important mosquito-borne viral disease in the world, with its incidence being increased 30-fold in the past 50 years. An epidemic of dengue/dengue haemorrhagic fever (DHF) is a major public health problem causing significant health and economic burden. The dengue crisis is further complicated by the lack of vaccines and antiviral drugs for prevention and control of this disease. This systematic review investigates and evaluates various studies done with homoeopathic therapy for the prevention and treatment of dengue fever. Objective Evaluate the usefulness of homoeopathy for a prevention and treatment of dengue fever through literature review and to develop the strategy for future research. Method A comprehensive search in electronic database aimed to target the available literature of observational studies, randomised trials, controlled trials, case studies on dengue fever in homoeopathy (excluding non–peer-reviewed journals) and limited to English language. Result A literary search through various databases helped identify a few significant studies as one double-blind placebo-controlled trial, one comparative clinical study, one case study and two community-based studies.The community-based studies showed positive results for the role of homoeopathic medicines as a prophylactic medicine. The double-blind placebo-controlled trial showed no difference in outcome between the two groups. The comparative clinical study showed that the homoeopathic combination appeared to be a more potent treatment against dengue fever when compare with standard maintenance therapy. The case study shows favourable results, but the sample size is only of 10 cases. Conclusion In future, high-quality randomised controlled trial (RCT), vitro and animal model studies are required to support the efficacy of homoeopathic therapeutics.

scholarly journals A double blind, randomised placebo controlled trial of topical 2% viscous lidocaine in improving oral intake in children with painful infectious mouth conditions

2011 ◽  
Vol 11 (1) ◽  
Author(s):  
Sandy M Hopper ◽  
Franz E Babl ◽  
Michelle McCarthy ◽  
Chasari Tancharoen ◽  
Katherine J Lee ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Oral Intake ◽  
Double Blind
Sign in / Sign up

Export Citation Format

Share Document